Ceapro Inc. (CRPOF)
- Previous Close
0.1700 - Open
0.1700 - Bid --
- Ask --
- Day's Range
0.1700 - 0.2060 - 52 Week Range
0.1150 - 0.3990 - Volume
6,000 - Avg. Volume
5,496 - Market Cap (intraday)
13.31M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date Aug 27, 2024 - Sep 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ceapro Inc., a biotechnology company, engages in the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using proprietary technology, natural, and renewable resources in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of the technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also develops and commercializes active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. The company was incorporated in 1997 and is headquartered in Edmonton, Canada. As of June 3, 2024, Ceapro Inc. operates as a subsidiary of Aeterna Zentaris Inc.
www.ceapro.comRecent News: CRPOF
Performance Overview: CRPOF
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRPOF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRPOF
Valuation Measures
Market Cap
12.88M
Enterprise Value
10.98M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.04
Price/Book (mrq)
0.70
Enterprise Value/Revenue
1.69
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-69.74%
Return on Assets (ttm)
-15.53%
Return on Equity (ttm)
-21.42%
Revenue (ttm)
8.91M
Net Income Avi to Common (ttm)
-6.22M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
4.75M
Total Debt/Equity (mrq)
8.28%
Levered Free Cash Flow (ttm)
-5.08M